Rolls-Royce share price faces a crucial test: rally or retreat ahead?
Rolls-Royce share price has lost the momentum it had last year as it faces some major external challenges that threaten its profit…
Asian tech stocks slide as AI rally loses momentum amid valuation worries
Asian semiconductor and technology stocks resumed their decline on Wednesday, tracking overnight weakness on Wall Street as concerns over artificial intelligence-related valuations…
UK equities hover at three-week lows as investors assess global risks
UK equity markets remained close to three-week lows on Wednesday as investors weighed ongoing geopolitical risks in the Middle East, corporate earnings…
Dow futures edge down as investors focus on US inflation
US stock futures traded lower during European hours on Wednesday as investors assessed escalating geopolitical tensions in the Middle East and prepared…
EURAUD Breakout: Aiming for 1.6600, 9 June, 2026
EURAUD currency pair can be expected to rise to the next resistance level 1.6600 (target price for the completion of the active…
Elev8 broker’s complete guide to trading commodity…
There are approximately 180 currencies in the world today exchanged daily via the foreign exchange market (Forex), the largest of its kind.…
SpaceX IPO (SPCX): Why This Could Be the Biggest Trading…
When Alibaba went public in 2014, it rewrote the record books and dominated trading desks for months. When Saudi Aramco listed in…
SpaceX IPO sparks global rally, Asian proxy plays lead gains
The upcoming initial public offering of SpaceX is triggering a wave of investor interest across Asia, with market participants seeking exposure to…
London’s FTSE 100 falls as GSK slides after Nuvalent deal
The UK’s benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans…
SpaceX IPO is oversubscribed now: is it time to invest?
SpaceX’s blockbuster IPO is attracting exactly the kind of demand many expected from Elon Musk’s most ambitious company. The offering is now…
GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here’s why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that…
Dow futures climb 125 points: 5 things to know before Wall Street opens
US stock-index futures advanced on Tuesday as chipmakers extended their rebound and easing tensions in the Middle East helped restore some appetite…